Alpha Tau Medical Ltd ( (DRTS) ) has issued an announcement.
On April 28, 2025, Alpha Tau Medical Ltd. announced the successful closing of a registered direct offering, raising approximately $36.9 million. The proceeds will be used for general corporate purposes, including research and development, manufacturing expansion, and potential commercialization of its products. Concurrently, Alpha Tau entered a strategic alliance with Oramed Pharmaceuticals, which will provide investor and public relations services over the next three years. This partnership is expected to support Alpha Tau’s ongoing growth, including multiple U.S. trial approvals and manufacturing scale-up.
Spark’s Take on DRTS Stock
According to Spark, TipRanks’ AI Analyst, DRTS is a Neutral.
Alpha Tau Medical Ltd’s stock score is heavily impacted by its financial performance challenges, particularly the lack of revenue and consistent operational losses. Despite positive technical indicators suggesting potential upward price momentum, the poor valuation metrics reflect the company’s unprofitability. Overall, the stock presents significant risks primarily due to its financial instability, though the technical analysis suggests some short-term trading opportunities.
To see Spark’s full report on DRTS stock, click here.
More about Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., founded in 2016 and based in Israel, is an oncology therapeutics company focused on the research, development, and potential commercialization of the Alpha DaRT® technology for treating solid tumors. This innovative therapy aims to deliver highly potent alpha-irradiation directly to tumors while sparing healthy tissue.
YTD Price Performance: -14.84%
Average Trading Volume: 56,482
Technical Sentiment Signal: Buy
Current Market Cap: $185.8M
For an in-depth examination of DRTS stock, go to TipRanks’ Stock Analysis page.